Form 4: Apellis Pharmaceuticals Chief Commercial Officer Sells Shares to Cover Tax Obligations

Adam J. Townsend, Chief Commercial Officer of Apellis Pharmaceuticals, sold 2,201 shares of common stock to cover tax withholding obligations related to restricted stock units.

Summary

• Adam J. Townsend, the Chief Commercial Officer of Apellis Pharmaceuticals, sold 2,201 shares of the company's common stock on January 17, 2025.
• The sale was executed at a price of $29.9582 per share.
• This transaction was to cover tax withholding obligations arising from the release of restricted stock units on January 16, 2025.
• Following the transaction, Townsend directly owns 88,068 shares of Apellis Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: This is a routine transaction for tax purposes and does not indicate any positive or negative sentiment towards the company's prospects.

Industry Context

This is a routine transaction for company executives to manage their tax obligations related to stock-based compensation. It is a common practice and does not necessarily indicate a change in the executive's outlook on the company.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the pharmaceutical industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales.
• The volume of shares sold is relatively small compared to the total shares held by the executive, which is typical in these situations.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a small transaction by an executive to cover tax obligations.

Key Dates

Keywords

Apellis Pharmaceuticals, Adam J. Townsend, stock sale, insider trading, Form 4, restricted stock units, tax withholding, chief commercial officer